We have recently reported the discovery of an entirely new category of potent antivaricella-zoster virus agents based on novel deoxynucleoside analogues bearing unusual fluorescent bicyclic furo base moieties. Initial studies revealed an absolute requirement of a long alkyl side-chain, with an optimal length of C8-C10, for antiviral activity. However, the impact of this requirement on the physical properties of these compounds is high: inherent lipophilicity and extremely poor aqueous solubility, which may limit the use of these nucleosides as drugs. In order to address this issue, we have now prepared a new series of analogues, bearing ether and glycol type side-chains, designed to improve the aqueous solubility of the compounds. Synthesis of target nucleosides involved Pd-catalysed coupling of terminal alkynes with 5-iodo-2′-deoxyuridine. The 5-alkynyl nucleosides thus obtained were then treated with copper (I) iodide to produce the desired bicyclic analogues. As anticipated, the new compounds exhibited a dramatic increase in aqueous solubility, although antiviral activity was significantly reduced. A possible correlation between antiviral activity and overall compound lipophilicity is discussed.
Many nucleoside analogues with potent biological properties have arisen by substitution at the 5-position of the uracil base, particularly in the 2′-deoxyuridine series. The 5-(2-substituted-vinyl)-2′-deoxyuridines in particular have emerged as potent and selective inhibitors of herpes virus replication, especially against herpes simplex virus type 1 (HSV-1) (De Clercq, 1980a , 1984 . 5-Alkynyl-2′-deoxyuridines have also been studied as potential antiviral agents, the parent 5-ethynyl system being a potent inhibitor of HSV-1, herpes simplex virus type 2 (HSV-2) and vaccinia virus (VV) (De Clercq et al., 1979 , 1980b . Whilst examining certain long chain 5-alkynyl-2′-deoxyuridines, we recently identified unusual bicyclic furo structures such as 1 (Figure 1 ) as potent and selective inhibitors of varicella-zoster virus (VZV) in cell culture (McGuigan et al., 1999) . Such compounds were previously known largely as synthetic by-products in the Pd-catalysed coupling of terminal alkynes with 5-substituted pyrimidines to generate 5-alkynyl systems (Robins & Barr, 1983; Kumar et al., 1991 Kumar et al., , 1996 Eger et al., 1995) , and their biological activity was surprising. Furthermore, the novel structures we reported displayed an unusual, but very clear, structure-activity relationship (SAR), in the form of an absolute requirement for a long alkyl side-chain on the base moiety for biological activity, with C8-C10 being optimal (McGuigan et al., 1999) . In subsequent studies, we showed that terminal substitution of halogens in the alkyl sidechain was well-tolerated, with full retention of activity down the group F, Cl, Br, I (Brancale et al., 2000) . We noted that the most active of the bicyclic nucleosides had calculated octanol-water logP [ClogP] (ClogP version 1.0.0; Biobyte, Claremont, Calif., USA) values in the range of 2.5-3.5, and noted a possible correlation between antiviral activity and overall compound lipophilicity (McGuigan et al., 2000a) . However, the inherent lipophilicity of these compounds has a significantly negative impact on their aqueous solubility and could limit their efficacy as antivirals. We were interested in increasing the aqueous solubility of these new nucleoside analogues, whilst seeking to retain 'optimal' lipophilicity. Thus, in this manuscript we describe the design, synthesis and evaluation of new analogues bearing ether and glycol type side-chains. 
Introduction

Materials and Methods
Chemistry
The numbering of the bicyclic ring follows the recommended IUPAC nomenclature guidelines. The naming of compounds follows IUPAC nomenclature and/or standard accepted nomenclature for nucleoside chemistry. For Thin Layer Chromatography precoated, aluminium-backed (60 F-54, 0.2 mm thickness; supplied by E Merck AG, Darmstadt, Germany) were used and were developed by the ascending method. After solvent evaporation, compounds were detected by quenching of the fluorescence at 254 or 366 nm, depending on the compound, on irradiation with a UV lamp. For column chromatography: glass columns were slurry packed in the appropriate eluent under gravity, with silica gel (C-gel 60A, 40-60 mm, Phase Sep, UK). Samples were applied as a concentrated solution in the same eluent, or pre-absorbed onto silica gel. Fractions containing the product were identified by thin layer chromatography, pooled, and the solvent removed in vacuo. Flash column chromatography was performed with the aid of a hand pump.
1 H and 13 C-NMR spectra were recorded on a Bruker Avance DPX300 spectrometer (300 and 75 MHz, respectively) and auto-calibrated to the deuterated solvent reference peak. Coupling constants (J) are given in Hertz (Hz). All 13 C-NMR spectra were proton-decoupled. Low resolution mass spectra were run on a Fisons VG Platform 8070 micromass spectrometer (atmospheric pressure ionization, elestrospray mass spectrometry) in positive ion mode, using a mobile phase of acetonitrile/water (1:1). High resolution mass spectra were obtained courtesy of the University of Birmingham, Department of Chemistry (Birmingham, UK).
All solvents used were anhydrous and used as supplied by Aldrich. All nucleosides and solid reagents were either dried for several hours while being heated under high vacuum over phosphorus pentoxide or by co-evaporation with dry pyridine. All glassware was oven-dried at 130°C for several hours or overnight, and allowed to cool in a desicator or under a stream of nitrogen.
4-(Heptyloxy)-1-butyne (3a)
. NaH (dispersion 60%, 3.36 g, 84.0 mmol) was added cautiously to a stirred solution of 3-butyn-1-ol (3.0 g, 42.0 mmol) in THF (25 ml), at 0°C under nitrogen. After 5 min, 1-iodoheptane (14.2 g, 63.0 mmol) was added and the mixture was stirred (18 h, rt). Further equivalents of NaH (dispersion 60%, 1.68 g, 42.0 mmol) and iodoheptane (9.4 g, 42.0 mmol) were added and the mixture was left to stir (20 h, rt). After quenching with water and extraction with ethyl acetate (EtOAc), the organic layer was washed with water, dried (MgSO 4 ) and filtered. The solvent was removed in vacuo and the residue was purified by distillation, yielding the pure product as a colourless oil (3.51 g, 50% 
5-(hexyloxy)-1-pentyne (3b)
. This was prepared as described for (3a) above, from 4-pentyn-1-ol (1.6 g, 19.5 mmol) in THF (10 ml), NaH (dispersion 60%, 1.56 g, 39.0 mmol), and 1-iodohexane (6.15 g, 29.0 mmol). The crude residue was purified by distillation; the first fraction gave the starting alkyne (0.6 g) and the middle fraction gave the pure product as a colourless oil (0.7 g, 35% 
6-(Pentyloxy)-1-hexyne (3c)
. This was prepared as described for (3a) above, from 5-hexyn-1-ol (4.0 g, 41.0 mmol) in THF (30 ml), NaH (dispersion 60%, 3.28 g, 82.0 mmol) and 1-iodopentane (12.2 g, 61.5 mmol). After 18 h, further equivalents of NaH (dispersion 60%, 1.64 g, 41.0 mmol) and iodopentane (8.2 g, 41.0 mmol) were added. The crude residue was purified by distillation, yielding the pure product as a colourless oil (2.75 g, 40% 
5-(2-Propoxyethoxy)-1-pentyne (3f)
. This was prepared as described above for 3e, from 4-pentyn-1-ol (3.0 g, 36.0 mmol) in THF (20 ml), NaH (dispersion 60%, 2.88 g, 72.0 mmol) and 1-(2-iodoethoxy)propane (11.56 g, 54.0 mmol). The crude residue was purified by distillation, separating 1.5 g of the starting alcohol and the pure product as a colourless oil (1.5 g, 25%; 50% based on consumed). δ H (CDCl 3 ) 3.62 (6H, m, 3×CH 2 ), 3.47 (2H, t, J 6.8 Hz,
CH 2 ), 2.33 (2H, dt, J 2.6 and J 7.1 Hz, HC≡CCH 2 ), 1.98 (1H, t, J 2.6 Hz, HC≡C), 1.85 (2H, m, CH 2 ), 1.65 (2H, m, CH 2 ), 0.96 (3H, t, J 7.4 Hz, CH 3 ); δ C (CDCl 3 ) 10.9 (CH 3 ), 15.6, 23.2, 28.9 (3 (CH 2 ), 68.8, 70.0, 70.4, 70.6, 73 .5 (4×CH 2 and α-alkynyl), 84.4 (β-alkynyl).
2-(3-Butynyl)-1,3-dioxane (3h).
Lithium acetylenideethylene diamine complex (4.092 g, 0.04 M), was suspended in dry DMSO (20 ml) and the temperature brought to 8°C. 2,2-Bromoethyl-1,3-dioxane (5.2 ml, 0.038 M) was added dropwise to the slurry, with the temperature maintained by external cooling. Upon completion of the addition, the mixture was allowed to warm to rt and stirred (1 h). Water (5 ml) was added, ensuring the internal temperature did not rise above 35°C. The hydrolysed reaction mixture was extracted three times with diethyl ether. The organics were dried (MgSO 4 ), filtered and the solvent removed in vacuo to give the product as a pale yellow oil (3.8 g, 68%). 
2-(3-Butynyl)-1,3-dioxolane (3i)
. This was prepared as described above for 3h, from lithium acetylenide-ethylene diamine complex (4.092 g, 0.04 M), dry DMSO (20 ml) and 2,2-bromoethyl-1,3-dioxolane (4.5 ml, 0.038 M). The product was isolated as a pale yellow oil (3.9 g, 77%).
, 31.7 (CH 2 ), 63.9, 64.0 (2×CH 2 ), 67.4 (α-alkynyl), 82.5 (β-alkynyl), 102.1 (CH).
5-[4-(Heptyloxy)-1-butynyl]-2′-deoxyuridine (4a).
To a stirred solution of 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol) in dry DMF (8 ml), at rt under a nitrogen atmosphere, were added diisopropylethylamine (0.584 g, 0.80 ml, 4.52 mmol), 4-(heptyloxy)-1-butyne (3a; 1.14 g, 6.78 mmol), tetrakis(triphenylphosphine)palladium(0) (0.261 g, 0.226 mmol) and copper (I) iodide (86 mg, 0.452 mmol). The reaction mixture was stirred (19 h, rt) and then concentrated in vacuo. The resulting residue was dissolved in dichloromethane (DCM)/methanol (MeOH) (1:1, 6 ml), an excess of Amberlite IRA-400 (HCO 3 -form) was added and the mixture was stirred (30 min). The reaction mixture was then filtered, washed with MeOH and the combined filtrate was evaporated to dryness. The residue was purified twice by silica column chromatography, using EtOAc as eluent. The solvent was removed in vacuo and trituration with diethyl ether gave the pure product as a white solid (0.49 g, 55%). 
5-[6-(Pentyloxy)-1-hexynyl]-2′-deoxyuridine (4c)
. This was prepared as described above for 4a, from 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), dry DMF (8 ml), diisopropylethylamine (0.584 g, 0.80 ml, 4.52 mmol), 6-(pentyloxy)-1-hexyne (3c; 1.14 g, 6.78 mmol), tetrakis(triphenylphosphine)palladium(0) (0.261 mg, 0.226 mmol) and copper (I) iodide (86 mg, 0.452 mmol). The product was purified three times by silica column chromatography, using EtOAc as eluent, and the combined filtrate was evaporated to dryness to yield the pure product as an off-white solid (0.45 g, 50% 
5-[7-(Butoxy)-1-heptynyl]-2′-deoxyuridine (4d)
. This was prepared as described above for 4a, from 5-iodo-2′-deoxyuridine 2 (0.4 g, 1.13 mmol), dry DMF (4 ml), diisopropylethylamine (0.292 g, 0.40 ml, 2.26 mmol), 7-(butoxy)-1-heptyne (3d; 0.707 g, 3.39 mmol), tetrakis(triphenylphosphine)palladium(0) (0.131 g, 0.113 mmol) and copper (I) iodide (43 mg, 0.226 mmol). The product was purified three times by silica column chromatography, using EtOAc as eluent, and the combined filtrate was evaporated to dryness to yield the pure product as an off-white solid (0.23 mg, 51%). 
5-[4-(Butoxyethoxy)-1-butynyl]-2′-deoxyuridine (4e).
This was prepared as described above for 4a, from 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), dry DMF (8 ml), diisopropylethylamine (0.584 g, 0.8 ml, 4.52 mmol), 4-(2-butenoxyethoxy)-1-butyne (3e; 1.15 g, 6.78 mmol), tetrakis (triphenylphosphine)palladium (0) 
5-[3-(Tetrahydro-2H-2-pyranyloxy)-1-propynyl]-2′-deoxyuridine (4g)
. This was prepared as described above for 4a, from 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), dry DMF (8 ml), di-isopropylethylamine (0.584 g, 0.8 ml, 4.52 mmol), tetrahydro-2,2-propynyl-oxy-2H-pyran (3g; 0.95 ml, 6.78 mmol), tetrakis (triphenyl-phosphine)palladium (0) 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[2-(heptyloxy)ethyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5a).
To a stirred solution of 5-[4-(heptyloxy)-1-butynyl]-2′-deoxyuridine (4a; 200 mg, 0.51 mmol) in MeOH/triethylamine (TEA) (7:3, 20 ml), at rt under a nitrogen atmosphere, was added copper (I) iodide (20 mg, 0.10 mmol). The reaction mixture was then heated to reflux and stirred (4 h). The solvent was removed in vacuo and the crude product purified by silica column chromatography, using an initial eluent of ethyl acetate, followed by an eluent of EtOAc/MeOH (9:1). The appropriate fractions were combined, the solvent removed in vacuo, and the residue triturated with diethyl ether to give the pure product as an offwhite solid (0.12 g, 60% 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[3-(hexyloxy)propyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5b).
To a stirred solution of 5-iodo-2′-deoxyuridine 2 (0.5 g, 1.41 mmol) in dry DMF (5 ml), at rt under a nitrogen atmosphere, were added di-isopropylethylamine (0.365 g, 2.82 mmol), 5-(hexyloxy)-1-pentyne (3b; 0.711 g, 4.23 mmol), tetrakis(triphenyl phosphine)palladium(0) (0.163 g, 0.141 mmol) and copper (I) iodide (53.7 mg, 4.23 mmol). The reaction mixture was stirred (20 h, rt), after which the reaction mixture was concentrated in vacuo. The resulting residue was dissolved in DCM/MeOH (1:1, 4 ml), an excess of Amberlite IRA-400 (HCO 3 -form) was added and the mixture was stirred (30 min). The reaction mixture was then filtered, washed with methanol and the combined filtrate was evaporated to dryness. The product was purified by silica column chromatography using DCM/MeOH (9:1) as eluent. Trituration with diethyl ether yielded the pure product as a pale cream solid (0.112 g, 20% 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[4-(pentyloxy)butyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5c)
. This was prepared as described above for 5a, from 5-[6-(pentyloxy)-1-hexynyl]-2′-deoxyuridine (4c; 200 mg, 0.51 mmol) and copper (I) iodide (20 mg, 0.10 mmol) in MeOH/TEA (7:3, 20 ml). The crude product was purified by silica column chromatography, using an initial eluent of EtOAc, followed by an eluent of EtOAc/MeOH (9:1), to give the pure product as an off-white solid (0.15 g, 75% 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[5-(butoxy)pentyl]-
2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5d)
. This was prepared as described for (5a) above, from 5-[7-(butoxy)-1-heptynyl]-2′-deoxyuridine (4d; 100 mg, 0.255 mmol) and copper (I) iodide (10 mg, 0.05 mmol) in MeOH/TEA (7:3, 10 ml). The crude product was purified twice by silica column chromatography, using an initial eluent of EtOAc, followed by an eluent of EtOAc/MeOH (9:1) to give the pure product as an off-white solid (60 mg, 60% 
3-(2′-Deoxy-β-D -ribofuranosyl)-6-[2-(butoxyethoxy)ethyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5e)
. This was prepared as described above for 5a, from 5-[4-(butoxyethoxy)-1-butynyl]-2′-deoxyuridine (4e; 200 mg, 0.50 mmol) and copper (I) iodide (20 mg, 0.10 mmol) in MeOH/TEA (7:3, 20 ml). The crude product was purified by silica column chromatography, using an initial eluent of EtOAc, followed by an eluent of EtOAc/MeOH (9:1), to give the pure product as an offwhite solid (0.14 g, 70%).
δ 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[3-(propoxyethoxy)-propyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5f).
This was prepared as described above for 5b, from 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), dry DMF (8 ml), diisopropylethylamine (0.584 g, 0.8 ml, 4.52 mmol), 5-(2-propoxyethoxy)-1-pentyne (3f; 1.15 g, 6.78 mmol), tetrakis (triphenylphosphine)palladium(0) (0.261 g, 0.226 mmol) and copper (I) iodide (86 mg, 0.452 mmol). The crude product was purified by silica column chromatography, using an initial eluent of DCM, followed by an eluent of DCM/MeOH (95:5) to give the pure product as an off-white solid (0.35 g, 40%). 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[(tetrahydro-2H-2-pyranyloxy)methyl]-2,3-dihydrofuro[2,3-d]pyrimidin-
2-one (5g).
To a stirred solution of 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), in dry DMF (8 ml), at rt under a nitrogen atmosphere, were added di-isopropylethylamine (0.584 g, 0.8 ml, 4.52 mmol), tetrahydro-2,2-propynyloxy-2H-pyran (3g; 0.95 ml, 6.78 mmol), tetrakis(triphenylphosphine)palladium (0) (0.261 g, 0.226 mmol) and copper (I) iodide (86 mg, 0.452 mmol). The reaction mixture was stirred (20 h, rt) after which time TEA (10 ml) and copper (I) iodide (80 mg) were added. The reaction mixture was heated to reflux and stirred (4 h), and then concentrated in vacuo. The resulting residue was dissolved in DCM/MeOH (1:1, 20 ml), an excess of Amberlite IRA-400 (HCO 3 -form) was added, and the suspension was stirred (30 min). The reaction mixture was then filtered, washed with methanol and the solvent removed in vacuo. The crude residue was purified by column chromatography, using MeOH:EtOAc (1:9) as eluent, to give the product as a cream solid (0.52 g, 63%). 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[2-(1,3-dioxan-2-yl)ethyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5h).
This was prepared as described above for 5g, from 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), dry DMF (7 ml), diisopropylethylamine (0.584 g, 0.8 ml, 4.52 mmol), 2-(3-butynyl)-1,3-dioxane (3h; 1.1 g, 7.85 mmol), tetrakis (triphenyl-phosphine)palladium (0) (0.261 g, 0.226 mmol) and copper (I) iodide (86 mg, 0.452 mmol). The crude residue was purified twice by column chromatography, using (i) MeOH:EtOAc (1:9) and (ii) MeOH:DCM (1:9) as eluent. Recrystallization from EtOAc/MeOH gave the product as a white solid (0.245 g, 30% 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-[2-(1,3-dioxolan-2-yl)ethyl]-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (5i).
This was prepared as described above for 5g, from 5-iodo-2′-deoxyuridine 2 (0.8 g, 2.26 mmol), dry DMF (7 ml), diisopropylethylamine (0.584 g, 0.8 ml, 4.52 mmol), 2-(3-butynyl)-1,3-dioxolane (3i; 1.0 g, 7.85 mmol), tetrakis(triphenyl-phosphine)palladium (0) (0.261 g, 0.226 mmol) and copper (I) iodide (86 mg, 0.452 mmol). The crude residue was purified twice by column chromatography, using (i) MeOH:EtOAc (1:9) and (ii) MeOH:DCM (1:9) as eluent. 
Materials and Methods
Virology
Cells. Human embryonic lung (HEL) fibroblasts and E 6 SM cells were grown in minimum essential medium (MEM) supplemented with 10% inactivated fetal calf serum (FCS), 1% L-glutamine and 0.3% sodium bicarbonate.
Viruses. The laboratory wild-type VZV strains OKA and YS, the thymidine kinase-deficient VZV strains 07-1 and YS-R, HSV-1 (strain KOS), HSV-2 (strain G), the thymidine kinase-deficient HSV-1 strains B-2006 and VMW 1837, human cytomegalovirus (HCMV) strains Davis and AD-169, and VV were used in the virus inhibition assays. Antiviral assays. Confluent HEL cells grown in 96-well microtitre plates were inoculated with VZV at an input of 20 plaque-forming units per well. After a 1-to 2-h incubation period, residual virus was removed and the infected cells were further incubated with MEM (supplemented with 2% inactivated FCS, 1% L-glutamine and 0.3% sodium bicarbonate) containing varying concentrations of the compounds. Antiviral activity was expressed as EC 50 (50% effective concentration), or compound concentration required to reduce viral plaque formation after 5 days by 50%, as compared to the untreated control. 3a: n=1, m=6 3b: n=2, m=5 3c: n=3, m=4
3e: n=2, m=1 3f: n=1, m=2 3h: n=3 3i: n=2 i, NaH, THF, 0°C-rt; ii, CH 3 (CH 2 )mI, rt; iii, PPh 3 , imidazole, I 2 , THF, rt; iv, HCCCH 2 (CH 2 ) m OH, NaH, THF, 0°C-rt; v, LiC≡CH.EDA, DMSO, 8°C
using a Coulter counter. The 50% cytostatic concentration (CC 50 ) was defined as the compound concentration required to reduce the cell number by 50%.
Results and Discussion
Chemistry
All target bicyclic nucleoside analogues were synthesized via the coupling of ω-alkynes with 5-iodo-2′-deoxyuridine 2, in dimethylformamide (DMF) under co-catalysis of Pd and Cu (McGuigan et al., 1999) . ω-Alkynes 3a-3d were prepared from the appropriate alkynyl alcohols and iodoalkanes, in the presence of sodium hydride (Figure 2) , and obtained in moderate-to-good yields after purification by distillation under reduced pressure. 6-Heptyn-1-ol, used in the preparation of 3d, was obtained by reduction of the cor- responding carboxylic acid with lithium aluminium hydride. The glycolic alkynes 3e and 3f were prepared from the appropriate alcohols and iodoalkyl ethers; the latter being synthesized in quantitative yield by treating the corresponding alcohols with molecular iodine in the presence of triphenylphospine and imidazole (Garegg & Samuelsson, 1980; Berlage et al., 1987) (Figure 2 ). Thus far, only bicyclic nucleoside analogues bearing linear sidechains have been studied. Therefore, we decided to introduce conformational constraints into the side-chain by preparing cyclic ether analogues. Tetrahydro-2,2-propynyloxy-2H-pyran, 3g, is commercially available, although the availability of other similar alkynes is limited. Thus, alkynes 3h and 3i were synthesized via a slightly modified literature method (Smith & Beumel, 1974) from the corresponding alkyl bromides, and obtained cleanly in good yields. Coupling of 2 with ω-alkynes 3a-3i using previously described conditions (McGuigan et al., 1999) gave the 5-alkynyl nucleosides 4, which, after treatment with copper (I) iodide in triethylamine/methanol, led to the desired fluorescent derivatives 5 in moderate-to-good yields ( Figure  3 ). In the case of products 5b and 5f-5i, these were generated in a one-pot reaction from 2, without isolation of the 5-alkynyl intermediates. Compounds 5a-5i were characterized by 1 H and 13 C-NMR and mass spectrometry.
Aqueous solubility
In order to quantify the aqueous solubility of these compounds, a series of experiments were conducted utilizing UV spectroscopy. Compound 3e, bearing two oxygen atoms in the side-chain, exhibits good aqueous solubility (>1 g/l). Thus, the extinction coefficient of a 1.0×10 -4 mol/l solution of 3e in water was calculated (λ max 244 nm) and the resulting value (9580 l/mol/cm) was then used to calculate the aqueous solubilities of 3c (bearing one oxygen atom in the sidechain) and 1 (lead compound). Compound 3c was found to be significantly less soluble than its glycol counterpart 3e, with a calculated solubility value of 123 mg/l (3.1×10 -4 mol/l). However, in the case of the lead compound 1, no UV spectrum was obtained, presumably due to the concentration of compound in solution being below the detection limit (estimated at <1 mg/l). The results clearly show that the modifications made in the side-chain have considerably increased the water solubility of these nucleosides;~100-fold for the ethers and >1000-fold for the glycols.
Antiviral activity
The target nucleosides 5a-5i, were evaluated for their ability to inhibit the replication of VZV in vitro, according to previously described method (McGuigan et al., 1999) . Data are shown in Table 1 for the activity of these compounds against two strains of thymidine kinase-competent VZV and two strains of thymidine kinase-deficient VZV. Data for the anti-herpetic agent acyclovir (ACV, Figure 1 ) and our previously reported furo compound 1 (McGuigan et al., 1999) are included for reference. Cytotoxicity data are also given for each compound in two assays (Table 1) . The data clearly revealed that introduction of one oxygen atom into the side-chain (compounds 5a-5d) resulted in a reduction of anti-VZV activity (~100-fold) compared to 1, and in the glycol and cyclic ether derivatives 5e-5i, activity appeared to be completely abolished. This may be rationalized, to some extent, by the relatively large decrease in ClogP values (bỹ 2.5) for the ether analogues compared to their corresponding parent alkyl derivatives. The further decrease in ClogP values for the glycol and cyclic glycol derivatives correlates well with their apparent abolition of antiviral activity. It is also interesting to note that although compounds 5a-d have constant ClogP values, there is some variation in activity between the analogues. This may correspond to changes in actual logP, not reflected in the calculated values, across the Table 1 . Anti-varicella-zoster virus activity and cytotoxicity for bicyclic nucleoside inhibitors (5a-5i) and reference compounds 1 and aciclovir series, or to conformational or other structural variation as the position of the ether oxygen is changed. As previously noted with other compounds of this class (McGuigan et al., 1999) , the present nucleosides displayed no antiviral activity in the thymidine kinase-deficient assays (Table 1) , which implies an absolute dependence on thymidine kinase-mediated activation for their biological activity. Further evaluation of 5a-5i against HCMV, HSV-1, HSV-2 and VV showed a complete absence of antiviral activity in cell culture (data not shown), indicating that the compounds are VZV-specific in their action. Moreover, all compounds displayed little or no cytotoxicity to uninfected cells, leading to a selectivity index for 5c of ~270. The results obtained here are disappointing; it was hoped that aqueous solubility could be improved without compromising potent antiviral activity, but this is clearly not the case. Nevertheless, the antiviral data shown in Table 1 are consistent with what would be expected on the basis of our recent findings regarding optimal lipophilicity (McGuigan et al., 2000a) , and strongly suggest that the presence of a highly lipophilic side-chain is fundamental to the antiviral activity of this class of compounds. To date, only a simple hydrocarbon chain of length C8-C10 appears to suffice; however, it may be that subtle structural modifications therein are still compatible with antiviral activity. Indeed, very recent data suggest that a phenyl group may substitute part of the hydrocarbon chain, and that such a substitution may lead to a further enhancement in the antiviral potency of the parent systems (McGuigan et al., 2000b) .
